3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Papillomavirus Infections
1
Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Financial Stress
1
Esophageal Neoplasms
1
Breast Neoplasms
1
Interventions
Carboplatin
11
pembrolizumab
10
Paclitaxel
10
Fluorouracil
9
Oxaliplatin
8
Radiotherapy
7
Nivolumab
7
Leucovorin
6
Cisplatin
6
Radiotherapy, Intensity-Modulated
5
Magnetic Resonance Spectroscopy
5
Taxes
4
durvalumab
3
Trastuzumab
3
Surgical Procedures, Operative
3
Capecitabine
3
relatlimab
2
Standard of Care
2
Specimen Handling
2
Radiation
2
Proton Therapy
2
Practice Guidelines as Topic
2
Irinotecan
2
Immune Checkpoint Inhibitors
2
Fluorodeoxyglucose F18
2
Drug Therapy
2
Docetaxel
2
Cetuximab
2
Blood Specimen Collection
2
zimberelimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Esophageal Neoplasms
×
Mass Screening
×
Clear all
NCT06335966
2026-03-17
BEST-RPP
OHSU Knight Cancer Institute
Active not recruiting
110 enrolled